PD ‐1 blockade enhances the effect of targeted chemotherapy on locally advanced pMMR / MSS colorectal cancer
Cancer Medicine · 2024
DOI: 10.1002/cam4.7224 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Fengyun Pei und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Colorectal Surgery, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Colorectal Neoplasms, Fluorouracil, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: 1010 Project of the Sixth Affiliated Hospital of Sun Yat-sen University, National Natural Science Foundation of China.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Patients with DNA mismatch repair‐proficient/microsatellite stable (pMMR/MSS) colorectal cancer (CRC), which accounts for 85% of all CRC cases, display a poor respond to immune checkpoint inhibitors (i.e., anti‐PD‐1 antibodies). pMMR/MSS CRC patients with locally advanced cancers need effective combined therapies.
Methods
In this pilot study, we administered six preoperative doses of each 2‐week cycle of the anti‐PD‐1 antibody sintilimab (at a fixed dose of 200 mg), oxaliplatin, and 5‐FU/CF (mFOLFOX6) combined with five doses of bevacizumab (the number of doses was reduced to prevent surgical delays) to patients with cT4NxM0 colon or upper rectal cancers. And radical surgery was performed approximately 2 weeks after the last dose of neoadjuvant therapy. The primary endpoint was a pathologic complete response (pCR). We also evaluated major pathologic response (MPR, ≤10% residual viable tumor), radiological and pathological regression, safety, and tumor mutation burden (TMB), and tumor microenvironment (TME) characteristics.
Results
By the cutoff date (September 2023), 22 patients with cT4NxM0 pMMR/MSS colon or upper rectal cancers were enrolled and the median follow‐up was 24.7 months (IQR: 21.1–26.1). All patients underwent R0 surgical resection without treatment‐related surgical delays. pCR occurred in 12 of 22 resected tumors (54.5%) and MPR occurred in 18 of 22 (81.8%) patients. At the cutoff date, all patients were alive, and 21/22 were recurrence‐free. Treatment‐related adverse events of grade 3 or higher occurred in of 2/22 (9.1%) patients. Among the pCR tumors, two were found to harbor POLE mutations. The degree of pathological regression was significantly greater than that of radiological regression ( p = 1.35 × 10 −8 ). The number of CD3+/CD4+ cells in the tumor and stroma in pretreated biopsied tissues was markedly lower in pCR tumors than in non‐pCR tumors ( p = 0.038 and p = 0.015, respectively).
Conclusions
Neoadjuvant sintilimab combined with bevacizumab and mFOLFOX6 was associated with few side effects, did not delay surgery, and led to pCR and non‐pCR in 54.5% and 81.8% of the cases, respectively. Downregulation of CD3/CD4 expression in the tumor and stroma is related to pCR. However, the molecular mechanisms underlying PD‐1 blockade‐enhanced targeted chemotherapy require further investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Colorectal Surgery, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
- Department of General Surgery, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
- Department of Oncology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, China.
- Department of Traditional Chinese Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
- Department of Pathology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
- Department of Radiation Oncology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Förderung
- 1010 Project of the Sixth Affiliated Hospital of Sun Yat-sen University
- National Natural Science Foundation of China
Zitieren
APA
Pei, F., He, W., Duan, Y., Yao, Q., Zhao, Y., Fan, X., Liu, S., Chen, H., He, F., Liu, T., Chen, J., Zheng, Y., Li, H., Guo, X., Shi, L., Ling, L., Chen, Y., He, J., Liu, M., …, & Huang, J. (2024). PD ‐1 blockade enhances the effect of targeted chemotherapy on locally advanced pMMR / MSS colorectal cancer. Cancer Medicine. https://doi.org/10.1002/cam4.7224
Vancouver
Pei F, He W, Duan Y, Yao Q, Zhao Y, Fan X, et al. PD ‐1 blockade enhances the effect of targeted chemotherapy on locally advanced pMMR / MSS colorectal cancer. Cancer Medicine. 2024. doi:10.1002/cam4.7224
BibTeX
@article{Pei2024,
author = {Pei, Fengyun and He, Wan and Duan, Yinghua and Yao, Qijun and Zhao, Yandong and Fan, Xinjuan and Liu, Shuai and Chen, Haiyang and He, Fang and Liu, Tingzhi and Chen, Jiaoting and Zheng, Yijia and Li, Heping and Guo, Xiaofang and Shi, Lishuo and Ling, Li and Chen, Yaoxu and He, Jiapeng and Liu, Miao and Huang, Mengli and Bai, Yuezong and Wang, Jianping and Huang, Meijin and Huang, Jun},
title = {PD ‐1 blockade enhances the effect of targeted chemotherapy on locally advanced pMMR / MSS colorectal cancer},
journal = {Cancer Medicine},
year = {2024},
doi = {10.1002/cam4.7224}
}
EUVIMED